UNSPSC 51432304: Imidaprilat

This classification denotes an ace inhibitor with the molecular formula C18H23N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WUU07Y30IA, chemically known as 4-imidazolidinecarboxylic acid, 3-((2s)-2-(((1s)-1-carboxy-3-phenylpropyl)amino)-1-oxopropyl)-1-methyl-2-oxo-, (4s)- but generally known as imidaprilat, which bears US NIH Compound Identifier 5464344. European Medicines Agency schedules Imidaprilat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08144MIG.

UNSPSC 51432304 Imidaprilat, a Commodity code, covers pharmaceutical active ingredients and finished-form medications that state and local governments procure for emergency medical services, public health programs, and institutional care settings. Recent activity shows state and local buyers soliciting advanced life support medications, generic pharmaceuticals, and specialty drug products through direct purchasing arrangements, cooperative purchasing vehicles, and manufacturer-to-wholesaler channels. The issuing bodies span city fire rescue departments, state health agencies, and multistate cooperative purchasing alliances, reflecting the diverse institutional demand for regulated pharmaceutical supply.

Activity concentrates in Florida, Texas, and Minnesota-Oregon cooperative purchasing regions. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, including a Small Local Business Enterprise sheltered market set-aside with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 due March 26, 2026 for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, requiring cGMP and Drug Supply Chain Security Act compliance and pricing through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson).